SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
OSUR

Orasure Technologies Inc (OSUR)

NASDAQ: OSUR · USD
Healthcare · Medical Instruments & Supplies
$3.46-$0.15 (-4.16%)
 
Market cap
$239M
Insider Score
Analyst consensus
Market Cap$238.90M+64.0%
Revenue (ttm)$116.23M
Net Income-$48.51M
EPS-$0.69
Shares Out69.05M
PE Ration/a
Forward PE-7.21
Dividendn/a
Ex-Dividend Daten/a
Volume502,791
Open$3.57
Previous Close$3.61
Day's Range$3.40 - $3.61
52-Week Range$2.28 - $4.58
Beta1.06
AnalystsBuy
Price Target$5.50(+58.96%)
Earnings DateNov 9, 2026

About OSUR

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.

Address
220 East First Street, Bethlehem, PA, 18015, United States
Market Cap
239 million
Employees
500
Industrial Classification
Medical Instruments & Supplies

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$546.16K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-4.16%
5 Days
-4.42%
1 Month
-8.95%
6 Months
-4.16%
1 Year
+63.98%

$OSUR stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of OSUR by members of U.S. Congress

Tom MalinowskiHouseSale$15.00K – $50.00KFeb 23, 2021
Tom MalinowskiHouseSale$1.00K – $15.00KJan 11, 2021
Tom MalinowskiHouseSale$15.00K – $50.00KDec 9, 2020
Tom MalinowskiHouseSale$15.00K – $50.00KOct 7, 2020

Recently reported changes in OSUR holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by OSUR's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

OSUR Estimated quarterly lobbying spending

Source: U.S. Senate LDA

OSUR Revenue by Segment or Geography

$30.93MTotal
Products and services$30.09M97.29%
Other$815.00K2.64%
COVID-19$22.00K0.07%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New OSUR patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to OSUR from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from OSUR’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
68.84
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
72

News check: Q3 2026 earnings show double-digit YoY growth and margin expansion; activist pressure resolved constructively through agreement with Altai Capital.

Recent Insider Activity

Buys
7
Sells
0
Buy Value
$546.16K
Distinct Buyers
3

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

GERMETFMG Treatments, Testing and Advancements ETF0.73%
QQQSInvesco NASDAQ Future Gen 200 ETF0.56%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.28%
PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF0.18%
PQSVPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Value ETF0.12%
DMRSDeltaShares S&P 600 Managed Risk ETF0.09%
IWCiShares Micro-Cap ETF0.06%
SLYSPDR S&P 600 Small Cap ETF0.05%
JPSEJPMorgan Diversified Return U.S. Small Cap Equity ETF0.04%
MSSMMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETF0.04%
PKWInvesco BuyBack Achievers ETF0.01%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.